Related Experiment Video
Updated: Aug 16, 2026
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
Published on: January 7, 2019
Development of fibroblast activation protein-α radiopharmaceuticals: Recent advances and perspectives
Ziyue Yu1, Zeng Jiang1, Xuebo Cheng1
1Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, 100069, China.
Abstract:
Fibroblast activation protein-α (FAP) has emerged as a promising target in the field of radiopharmaceuticals due to its selective expression in cancer-associated fibroblasts (CAFs) and other pathological conditions involving fibrosis and inflammation. Recent advancements have focused on developing FAP-specific radioligands for diagnostic imaging and targeted radionuclide therapy. This perspective summarized the latest progress in FAP radiopharmaceutical development, highlighting novel radioligands, preclinical evaluations, and potential clinical applications. Additionally, we analyzed the advantages and existing problems of targeted FAP radiopharmaceuticals, and discussed the key breakthrough directions of this target, so as to improve the development and conversion of FAP-targeted radiopharmaceuticals.
Insights
Fibroblast activation protein-α (FAP) radiopharmaceuticals show promise for cancer imaging and therapy. This review covers recent advances in FAP-targeted radioligands, their preclinical and clinical potential, and future development directions.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical science
- Oncology
Background:
- Fibroblast activation protein-α (FAP) is highly expressed in cancer-associated fibroblasts (CAFs).
- FAP is also implicated in fibrosis and inflammation, making it a versatile target.
- Targeted radiopharmaceuticals offer precise diagnostic and therapeutic capabilities.
Purpose of the Study:
- To review recent progress in developing FAP-specific radiopharmaceuticals.
- To highlight novel radioligands and their preclinical/clinical evaluations.
- To discuss challenges and future directions for FAP-targeted therapies.
Main Methods:
- Literature review of FAP radiopharmaceutical development.
- Analysis of preclinical data and clinical trial outcomes.
- Discussion of FAP expression patterns in various diseases.
Main Results:
- Several novel FAP-specific radioligands have been developed.
- Promising preclinical results for imaging and therapy have been reported.
- Early clinical investigations are underway, demonstrating feasibility.
Conclusions:
- FAP-targeted radiopharmaceuticals represent a significant advancement in cancer diagnostics and therapy.
- Further research is needed to overcome existing challenges and optimize clinical translation.
- Key breakthrough directions include improved ligand design and combination therapies.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
